Comparing limertinib with or without bevacizumab for first-line NSCLC
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if adding bevacizumab to the targeted therapy limertinib works better than limertinib alone for people with advanced non-squamous non-small cell lung cancer that has a specific EGFR mutation and high PD-L1 levels. You cannot have had prior treatment with these types of drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced (Stage IIIB–IV) non-squamous non-small cell lung cancer that cannot be removed with surgery or treated with radiation.
- Your cancer has a common EGFR mutation (Ex19del or L858R) and your PD-L1 score is 25% or higher.
- You have not previously received an EGFR-targeted pill or an anti-angiogenic drug like bevacizumab.
- You are in good overall health (ECOG 0 or 1) and have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs (QL1706 and bevacizumab) with or without chemotherapy for people with advanced non-squamous lung cancer whose cancer worsened after prior immunotherapy. It may offer a new option for those with low PD-L1 levels.
This trial tests a targeted pill (Limertinib) combined with radiation therapy for people with a specific type of lung cancer (EGFR mutation) that has spread to the brain. The goal is to see if this combination shrinks brain tumors and keeps them from growing.
This trial tests whether adding a cholesterol-lowering drug to a combination of two other drugs can help people with advanced non-small cell lung cancer whose cancer has grown after prior immunotherapy. It aims to find a new treatment option for those who have run out of standard options.
This trial tests a new targeted therapy (DZD9008) combined with a drug that blocks blood vessel growth (bevacizumab) for people with a specific type of advanced lung cancer (EGFR mutation). The goal is to see if this combination works better than current treatments.
This trial tests whether combining a targeted therapy (Firmonertinib) with a drug that blocks blood vessel growth (bevacizumab/Avastin) before surgery can shrink tumors in people with a specific type of lung cancer (EGFR mutation-positive, stages II–IIIB). The goal is to increase the chance of successful surgery.
This trial compares a combination of anti-angiogenics (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) against Avastin-based treatment in people with advanced non-small cell lung cancer. It aims to find out whether the study treatment is safer and works better for shrinking tumors and improving outcomes.
Hear when a new EGFR Mutation Positive Advanced Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.